Table 1.
Baseline clinical characteristics of all patients.
| Parameters | Total (n=238) | IM (n=126) | IM+HR (n=81) | IM+RFA/ TACE (n=31) | P | SMD |
|---|---|---|---|---|---|---|
| Age (years) | 0.297 | 0.150 | ||||
| ≤60 | 164 (68.91) | 82 (65.08) | 61 (75.31) | 21 (67.74) | ||
| >60 | 74 (31.09) | 44 (34.92) | 20 (24.69) | 10 (32.26) | ||
| Sex | 0.799 | 0.092 | ||||
| Female | 80 (33.61) | 42 (33.33) | 26 (32.10) | 12 (38.71) | ||
| Male | 158 (66.39) | 84 (66.67) | 55 (67.90) | 19 (61.29) | ||
| Primary sites | 0.496 | 0.239 | ||||
| Stomach | 91 (38.24) | 43 (34.13) | 32 (39.51) | 16 (51.61) | ||
| Small intestine | 134 (56.30) | 76 (60.32) | 45 (55.56) | 13 (41.94) | ||
| Colorectum | 5 (2.10) | 3 (2.38) | 2 (2.47) | 0 (0.00) | ||
| Others | 8 (3.36) | 4 (3.17) | 2 (2.47) | 2 (6.45) | ||
| Metastatic phase | 0.064 | 0.209 | ||||
| Synchronous | 98 (41.18) | 43 (34.13) | 40 (49.38) | 15 (48.39) | ||
| Metachronous | 140 (58.82) | 83 (65.87) | 41 (50.62) | 16 (51.61) | ||
| Number of metastases | <0.001 | 0.518 | ||||
| ≤3 | 105 (44.12) | 35 (27.78) | 52 (64.20) | 18 (58.06) | ||
| >3 | 133 (55.88) | 91 (72.22) | 29 (35.80) | 13 (41.94) | ||
| Largest diameter of metastases (cm) | 0.313 | 0.211 | ||||
| ≤3 | 122 (51.26) | 66 (52.38) | 37 (45.68) | 19 (61.29) | ||
| >3 | 116 (48.74) | 60 (47.62) | 44 (54.32) | 12 (38.71) | ||
| Extrahepatic metastases | 0.687 | 0.080 | ||||
| No | 157 (65.97) | 80 (63.49) | 56 (69.14) | 21 (67.74) | ||
| Yes | 81 (34.03) | 46 (36.51) | 25 (30.86) | 10 (32.26) | ||
| Gene mutation | 0.806 | 0.131 | ||||
| KIT_exon 9 | 27 (11.34) | 14 (11.11) | 8 (9.88) | 5 (16.13) | ||
| KIT_exon 11 | 105 (44.12) | 51 (40.48) | 40 (49.38) | 14 (45.16) | ||
| Wild type | 10 (4.20) | 6 (4.76) | 4 (4.94) | 0 (0.00) | ||
| Others | 4 (1.68) | 2 (1.59) | 1 (1.23) | 1 (3.23) | ||
| Unknown | 92 (38.66) | 53 (42.06) | 28 (34.57) | 11 (35.48) | ||
| IM response before surgical treatmenta | 0.615 | 0.180 | ||||
| PR | 9 (8.04) | — | 8 (9.88) | 1 (3.23) | ||
| SD | 34 (30.36) | — | 23 (28.40) | 11 (35.48) | ||
| Extensive progression | 6 (5.36) | — | 4 (4.94) | 2 (6.45) | ||
| Limited progression | 27 (24.11) | — | 18 (22.22) | 9 (29.03) | ||
| NA | 36 (32.14) | — | 28 (34.57) | 8 (25.81) | ||
| Status after surgical treatmenta | 0.018 | 0.517 | ||||
| NED | 60 (53.57) | — | 49 (60.49) | 11 (35.48) | ||
| non-NED | 52 (46.43) | — | 32 (39.51) | 20 (64.52) | ||
| Combined with other local therapy | — | — | ||||
| No | — | — | 63 (77.78) | — | ||
| RFA | — | — | 15 (18.52) | — | ||
| TACE | — | — | 2 (2.47) | — | ||
| RFA+TACE | — | — | 1 (1.23) | — |
Values are presented as n (%).
P-values were calculated using a two-sided χ2 test.
a
Suitable for surgical treatment group (n=112).
HR, hepatic resection; IM, imatinib; NA, not applicable; NED, no evidence of disease; PR, partial response; RFA, radiofrequency ablation; SD, stable disease; SMD, standard mean difference; TACE, transarterial chemoembolization.